Earth Science Tech Expands Pharmacy Network with Meduvo Acquisition, Reaching 34 U.S. Jurisdictions

Earth Science Tech, Inc. (OTC: ETST) has announced the acquisition of Meduvo LLC, a compounding pharmacy based in La Verne, California, marking a significant step in the company's expansion strategy. This acquisition establishes a West Coast operational hub and broadens ETST's pharmacy network to 34 U.S. jurisdictions, a move that underscores the company's commitment to building a vertically integrated healthcare platform.

The newly acquired Meduvo operates from a 2,000-square-foot facility and currently compounds and dispenses non-sterile medications. ETST has initiated facility upgrades designed to meet sterility requirements, with management targeting full regulatory certification for sterile compounding by the end of 2028. This strategic investment positions the company to offer a wider range of compounded medications, including those that require sterile preparation, which is a growing segment in the pharmaceutical industry.

The acquisition comes as part of ETST's broader strategy to integrate compounding pharmacy operations with telemedicine platforms, clinical support, and direct-to-patient fulfillment. By expanding its geographic footprint, the company aims to enhance its ability to serve patients across the United States. Regulatory approvals are pending in additional states as ETST pursues nationwide coverage, indicating a clear trajectory toward becoming a national player in the healthcare sector.

This expansion is particularly important as the demand for personalized medicine and compounded medications continues to rise. Compounding pharmacies play a crucial role in providing tailored treatments for patients who cannot use commercially available drugs due to allergies, dosage requirements, or other medical needs. By increasing its network and capabilities, ETST is positioning itself to meet this demand more effectively.

The company's focus on achieving sterile compounding certification is also noteworthy, as sterile compounding is subject to stringent regulatory standards. This certification would allow ETST to offer a broader range of products, including injectables and ophthalmic preparations, which are often in high demand. The targeted timeline of 2028 reflects a realistic approach to navigating the complex regulatory landscape.

For investors, this acquisition signals ETST's proactive approach to growth and its dedication to expanding its operational capabilities. The move is likely to enhance the company's revenue potential and market competitiveness. As the healthcare industry evolves, companies that can offer integrated solutions from consultation to fulfillment are poised to thrive.

Earth Science Tech's acquisition of Meduvo is a clear indication of its strategic vision. The establishment of a West Coast hub not only diversifies its geographic presence but also strengthens its supply chain and distribution capabilities. This is a positive development for the company and its stakeholders.

The full press release can be viewed at https://ibn.fm/wMvIu. For more information on Earth Science Tech, visit its newsroom at https://ibn.fm/ETST.